Sort
48,018 grants matching “immunotherapy”
Metabolic control of regulatory T cell functional identity
$602,526Greg M. Delgoffe · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · AI
Antigenic determinants of asthma-associated allergens for design of immunotherapy.
$602,515Anna Pomes · Indoor Biotechnologies · R01 · FY2018 · AI
Targeting retrotransposons for improved treatment of refractory childhood cancer
$602,486Andrei V Gudkov · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA
Endothelial-Leukocyte Adhesion in CAR T Cell Treatment Associated Neurotoxicity
$602,466Juliane Gust · Seattle Children'S Hospital · R37 · FY2023 · CA
Reprogramming myeloid cell metabolism to prevent cognitive aging and Alzheimer's Disease
$602,463Katrin I Andreasson · Stanford University · R01 · FY2025 · AG
(PQ3) Immune epigenetic biomarkers of bladder cancer outcomes
$602,394Brock Clarke Christensen · Dartmouth College · R01 · FY2018 · CA
VPS72 controls Treg cell stability and adaptation to tumor microenvironment
$602,346Qing-Sheng Mi · Henry Ford Health + Michigan State University Health Sciences · R01 · FY2024 · CA
Molecular recognition of proteins by antibodies: A model for rational design
$602,202Sandra Smith-Gill · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Mucosal Chemokines and CD8+ T Cell Immunity to Genital Herpes
$602,162Lbachir Benmohamed · University Of California-Irvine · R01 · FY2020 · AI
Identifying correlates of protection afforded by (Delta)GY SIVmac239 attenuated virus vaccine
$602,145Pyone Aye · Tulane University Of Louisiana · N01 · FY2020 · AI
Mechanisms of immune homeostasis and regulation of intraocular inflammation
$602,114Charles E Egwuagu · National Eye Institute · ZIA · FY2022 · EY
A New Multimodal Molecular Imaging Approach to Guide Intra-Operative Tumor Resection and Post-Operative Treatment Planning
$602,097Cristina L. Zavaleta · University Of Southern California · R01 · FY2024 · EB
Regulatory T Cells and Pulmonary Hypertension
$602,055Mark Robert Nicolls · Palo Alto Veterans Instit For Research · R01 · FY2023 · HL
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer
$602,006Yoon Yeo · Purdue University · R01 · FY2021 · CA
High-content functional cancer drug testing on micro-cuboidal tumor dissections
$601,999Albert Folch · University Of Washington · R21 · FY2020 · CA
CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages
$601,993David Allen Ralph · Navidea Biopharmaceuticals, Inc. · R44 · FY2018 · CA
IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors
$601,989Andras A. Heczey · Baylor College Of Medicine · R01 · FY2024 · CA
Preclinical development of breakthrough immunotherapy for brain tumors
$601,887Hideho Okada · University Of California, San Francisco · R35 · FY2018 · NS
A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and Radiation
$601,792Amy Beth Heimberger · Northwestern University At Chicago · R01 · FY2023 · CA
Fecal microbial transplantation for chemotherapy behavioral side effects
$601,697Leah M Pyter · Ohio State University · R01 · FY2025 · CA
Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers
$601,640Zachary Conrad Hartman · Duke University · R01 · FY2022 · CA
Myeloid-lineage cells and immunopathology in Leishmania braziliensis
$601,620Phillip A. Scott · University Of Pennsylvania · U01 · FY2012 · AI
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
$601,546Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2022 · CA
Integrating Radiomics into S0819 and Lung-MAP, Biomarker Driven Clinical Trials for Lung Cancer
$601,400Lawrence H Schwartz · Columbia University Health Sciences · U01 · FY2019 · CA
Tumor-associated macrophages in vasogenic cerebral edema in brain tumors
$601,382Dolores Hambardzumyan · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · NS